PHOTOCURE ASA NK-50
Research PHOTOCURE ASA NK-50 (PHS) on Bullrun: valuation model: 3.4% undervalued, market cap EUR 139.15M, P/E 18.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPHS
- ExchangeF
- CountryNorway
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Valuation signal3.4% undervalued
- Market capEUR 139.15M
- P/E18.7
- Financial periodFY2024
- RevenueNOK 525.39M
- Revenue growth4.9%
- Net income-NOK 3.34M
- Free cash flowNOK 65.30M
- Gross margin94.2%
Valuation Snapshot
Bullrun's latest valuation model marks PHOTOCURE ASA NK-50 as 3.4% undervalued; latest market cap is EUR 139.15M; P/E is 18.7.
About PHOTOCURE ASA NK-50
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia.
Frequently asked questions
Is PHOTOCURE ASA NK-50 overvalued or undervalued?
Bullrun's valuation model currently marks PHOTOCURE ASA NK-50 as 3.4% undervalued.
What is PHOTOCURE ASA NK-50's market cap?
PHOTOCURE ASA NK-50's market capitalization is EUR 139.15M.
What is PHOTOCURE ASA NK-50's P/E ratio?
PHOTOCURE ASA NK-50's price-to-earnings (P/E) ratio is 18.7.
What does PHOTOCURE ASA NK-50 do?
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio.